Drug intelligence / Profile preview

Lodient

Development stage
Phase 1
Modality
Small Molecules
Administration
Oral
01

Overview

**Lodient** is a fixed-dose combination tablet containing telmisartan, an angiotensin II receptor blocker (ARB), and S-amlodipine, a calcium channel blocker (CCB), used for the treatment of hypertension. It combines the blood pressure-lowering effects of telmisartan, which selectively blocks the angiotensin II type 1 (AT1) receptor to inhibit vasoconstriction and aldosterone release, with S-amlodipine, the active enantiomer of amlodipine that inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. Available as an 80/2.5 mg formulation (telmisartan/S-amlodipine), it is prescribed to patients requiring dual therapy for better blood pressure control, with ongoing observational studies evaluating its prescription patterns and efficacy in reducing hypertension symptoms.[5][9][10][11]

Brand names
Lodient
Other names
telmisartan/amlodipinetelmisartan/S-amlodipine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on Lodient.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lodient.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call